Delivers unsurpassed pain relief and improvement in function SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (0A) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, eg, acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these SYNVISC and GENZYME are registered trademarks of Genzyme Corporation. ©2007 Genzyme Corporation. All rights reserved. Printed in USA. S-00010.B 01/2007 NO VISCOSUPPLEMENT STANDS UP TO PAIN BETTER 189
RkJQdWJsaXNoZXIy NDMwNDAx